Medpace Holdings (MEDP) EBITDA Margin (2015 - 2026)
Medpace Holdings' (MEDP) quarterly EBITDA Margin came in at 21.68% in Q2 2026, down 38.0% on a YoY basis from 34.97% in Q2 2025, and up 3.35% quarter-over-quarter from 20.98% in Q1 2026.
Powered by 
Analysis
Medpace Holdings (MEDP) EBITDA Margin (2015 - 2026) Analysis & Trends
Medpace Holdings (MEDP) has reported EBITDA Margin for 12 consecutive years, with 21.68% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 38.0% year-over-year to 21.68%; the trailing twelve-month figure through Jun 2026 stood at 21.94% (down 70.0% YoY), and the FY2025 full-year result was 22.22%, down 29.0% from the prior year.
- EBITDA Margin grew to 21.68% in Q2 2026 per MEDP's latest filing, from 20.98% in the prior quarter.
- Across five years, EBITDA Margin topped out at 24.7% in Q4 2024 and bottomed at 18.31% in Q2 2023.
- Historically, EBITDA Margin has averaged 21.08% across 5 years, with a median of 21.37% in 2025.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 305 bps in 2023, then soared 589 bps in 2024.
- Over 5 years, EBITDA Margin stood at 20.68% in 2022, then decreased by 9 bps to 18.81% in 2023, then jumped by 31 bps to 24.7% in 2024, then dropped by 8 bps to 22.61% in 2025, then retreated by 4 bps to 21.68% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 21.68%, 20.98%, and 22.61% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 11.58% |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 21.68% |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 15.86% |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 11.94% |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 2.18% |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | -290.47% |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -2.69% |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -218,381.69% |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -15,327.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.68% |
| Mar 31, 2026 | 20.98% |
| Dec 31, 2025 | 22.61% |
| Sep 30, 2025 | 22.52% |
| Jun 30, 2025 | 22.06% |
| Mar 31, 2025 | 21.52% |
| Dec 31, 2024 | 24.70% |
| Sep 30, 2024 | 22.39% |
| Jun 30, 2024 | 21.21% |
| Mar 31, 2024 | 21.66% |
| Dec 31, 2023 | 18.81% |
| Sep 30, 2023 | 18.53% |
| Jun 30, 2023 | 18.31% |
| Mar 31, 2023 | 21.11% |
| Dec 31, 2022 | 20.68% |
| Sep 30, 2022 | 21.57% |
| Jun 30, 2022 | 18.49% |
| Mar 31, 2022 | 20.69% |
| Dec 31, 2021 | 19.13% |
| Sep 30, 2021 | 19.55% |